Mechanisms, function and clinical applications of DNp73

Cell Cycle

Volumn 12, Issue 12, 2013, Pages 1861-1867

  Di, Cuixia ^a,c,d   Yang, Lina ^b   Zhang, Hong ^a,c,d   Ma, Xiaofei ^a,c,d   Zhang, Xin ^a,c,d   Sun, Chao ^a,c,d   Li, Hongyan ^a,c,d   Xu, Shuai ^a,c,d   An, Lizhe ^b   Li, Xun ^b   Bai, Zhongtian ^b  

^a INSTITUTE OF MODERN PHYSICS   (China)

^b LANZHOU UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d Key Laboratory of Heavy Ion Radiation Medicine of Gansu Province   (China)

Author keywords

Alternative splicing; Apoptosis; Cancer; Chemosensitivity; DNp73; Radiotherapy; Tumorigenesis

Indexed keywords

ISOPROTEIN; PROTEIN P73;

ACUTE GRANULOCYTIC LEUKEMIA; ALZHEIMER DISEASE; AMELOBLASTOMA; APOPTOSIS; BIOLOGICAL FUNCTIONS; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CANCER THERAPY; CARCINOGENICITY; CELL FUNCTION; CHEMOSENSITIVITY; COLON CANCER; DISEASE SEVERITY; DNA BINDING; ESOPHAGUS TUMOR; EXON; GENE EXPRESSION; GENE OVEREXPRESSION; GYNECOLOGIC CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IN VIVO STUDY; INTRON; KIDNEY DEVELOPMENT; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OLIGOMERIZATION; OSTEOSARCOMA; OVARY CANCER; PARKINSON DISEASE; PRIMARY TUMOR; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHABDOMYOSARCOMA; STOMACH TUMOR; THYROID CARCINOMA; TRANSACTIVATION; TRANSGENIC MOUSE; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

EID: 84879373640     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24967     Document Type: Review

References (92)

1. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90:809-19; PMID:9288759; http://dx.doi.org/10.1016/S0092-8674(00)80540-1 (Pubitemid 27357971)
2. Liu K, Zhuang X, Mai Z. p73 expression is associated with cellular chemosensitivity in human non-small cell lung cancer cell lines. Oncol Lett 2013; 5:583-7; PMID:23420689
3. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV, et al. p73 in Cancer. Genes Cancer 2011; 2:491-502; PMID:21779517; http://dx.doi.org/10.1177/1947601911408890
4. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, et al. p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun 2005; 331:713-7; PMID:15865927; http://dx.doi.org/10.1016/j.bbrc.2005.03.156 (Pubitemid 40615502)
5. Bailey SG, Cragg MS, Townsend PA. Family friction as ?Np73 antagonises p73 and p53. Int J Biochem Cell Biol 2011; 43:482-6; PMID:21216303; http://dx.doi.org/10.1016/j.biocel.2010.12.022
6. Muppani N, Nyman U, Joseph B. TAp73alpha protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death. Oncotarget 2011; 2:1145-54; PMID:22201672
7. Conforti F, Yang AL, Agostini M, Rufini A, Tucci P, Nicklison-Chirou MV, et al. Relative expression of TAp73 and ?Np73 isoforms. Aging (Albany NY) 2012; 4:202-5; PMID:22388545
8. Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998; 58:5061-5; PMID:9823311 (Pubitemid 28521161)
9. Blandino G, Dobbelstein M. p73 and p63: Why do we still need them? Cell Cycle 2004; 3:886-94; PMID:15254416; http://dx.doi.org/10.4161/cc.3.7.996 (Pubitemid 40179467)
10. Tissir F, Goffinet AM. p73 and p63: Estranged relatives? Cell Cycle 2011; 10:1351; PMID:21460637; http://dx.doi.org/10.4161/cc.10.9.15383
11. Rosenbluth JM, Pietenpol JA. The jury is in: P73 is a tumor suppressor after all. Genes Dev 2008; 22:2591-5; PMID:18832062; http://dx.doi.org/10.1101/ gad.1727408
12. Stiewe T, Pützer BM. Role of p73 in malignancy: Tumor suppressor or oncogene? Cell Death Differ 2002; 9:237-45; PMID:11859406; http://dx.doi.org/10. 1038/sj.cdd.4400995 (Pubitemid 34223867)
13. Buhlmann S, Pützer BM. DNp73 a matter of cancer: Mechanisms and clinical implications. Biochim Biophys Acta 2008; 1785:207-16; PMID:18302944
14. Domínguez G, García JM, Peña C, Silva J, García V, Martínez L, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: Putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006; 24:805-15; PMID:16380414; http://dx.doi.org/10.1200/JCO.2005.02.2350 (Pubitemid 46622048)
15. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002; 196:765-80; PMID:12235210; http://dx.doi.org/10.1084/jem.20020179
16. Soldevilla B, Díaz R, Silva J, Campos-Martín Y, Muñoz C, García V, et al. Prognostic impact of ?TAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res 2011; 17:6029-39; PMID:21807636; http://dx.doi.org/10.1158/1078-0432.CCR-10-2388
17. He Y, Fan S, Jiang Y, Xue Z. Expression of ?Np73 in human NSCLC and clinical implication. Zhongguo Fei Ai Za Zhi 2006; 9:263-6; PMID:21172158 (Pubitemid 44013529)
18. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, et al. Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 2004; 10:6905-11; PMID:15501968; http://dx.doi.org/10.1158/1078-0432.CCR-04-0290 (Pubitemid 39383040)
19. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, et al. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004; 64:2449-60; PMID:15059898; http://dx.doi.org/10.1158/0008-5472.CAN-03- 1060 (Pubitemid 38523899)
20. Hofstetter G, Berger A, Chamson M, Müller-Holzner E, Reimer D, Ulmer H, et al. Clinical relevance of TAp73 and ?Np73 protein expression in ovarian cancer: A series of 83 cases and review of the literature. Int J Gynecol Pathol 2011; 30:527-31; PMID:21979586; http://dx.doi.org/10.1097/PGP.0b013e31821ac519
21. Hofstetter G, Berger A, Chamson M, Müller-Holzner E, Reimer D, Ulmer H, et al. Clinical relevance of TAp73 and ?Np73 protein expression in ovarian cancer: A series of 83 cases and review of the literature. Int J Gynecol Pathol 2011; 30:527-31; PMID:21979586; http://dx.doi.org/10.1097/PGP.0b013e31821ac519
22. Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW, Ngan HY. Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 2006; 12:3922-7; PMID:16818688; http://dx.doi.org/10.1158/1078-0432.CCR-05-2573 (Pubitemid 44078076)
23. Puppin C, Passon N, Frasca F, Vigneri R, Tomay F, Tomaciello S, et al. In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription. Cell Oncol (Dordr) 2011; 34:131-40; PMID:21290209; http://dx.doi.org/10.1007/s13402-011-0009-9
24. Vella V, Puppin C, Damante G, Vigneri R, Sanfilippo M, Vigneri P, et al. DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells. Int J Cancer 2009; 124:2539-48; PMID:19173293; http://dx.doi.org/10.1002/ijc.24221
25. Frasca F, Vella V, Aloisi A, Mandarino A, Mazzon E, Vigneri R, et al. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 2003; 63:5829-37; PMID:14522906 (Pubitemid 37187481)
26. Rizzo MG, Giombini E, Diverio D, Vignetti M, Sacchi A, Testa U, et al. Analysis of p73 expression pattern in acute myeloid leukemias: Lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia 2004; 18:1804-9; PMID:15385938; http://dx.doi.org/10.1038/sj.leu. 2403483 (Pubitemid 39530009)
27. Simões-Wüst AP, Sigrist B, Belyanskaya L, Hopkins Donaldson S, Stahel RA, Zangemeister-Wittke U. DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells. J Neurooncol 2005; 72:29-34; PMID:15803372; http://dx.doi.org/10.1007/s11060-004-3118-8 (Pubitemid 41149174)
28. Douc-Rasy S, Barrois M, Echeynne M, Kaghad M, Blanc E, Raguenez G, et al. DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol 2002; 160:631-9; PMID:11839584; http://dx.doi.org/10.1016/S0002-9440(10)64883-3 (Pubitemid 34160341)
29. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002; 9:246-51; PMID:11859407; http://dx.doi.org/10.1038/sj.cdd.4400993 (Pubitemid 34223868)
30. Guan M, Chen Y. Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: Correlation with Gleason score. J Clin Pathol 2005; 58:1175-9; PMID:16254107; http://dx.doi.org/10.1136/jcp.2005.026955 (Pubitemid 41566462)
31. Niemantsverdriet M, Nagle P, Chiu RK, Langendijk JA, Kampinga HH, Coppes RP. ?Np73 enhances promoter activity of TGF-ß induced genes. PLoS One 2012; 7:e50815; PMID:23236396; http://dx.doi.org/10.1371/journal.pone.0050815
32. Vilgelm AE, Hong SM, Washington MK, Wei J, Chen H, El-Rifai W, et al. Characterization of ?Np73 expression and regulation in gastric and esophageal tumors. Oncogene 2010; 29:5861-8; PMID:20676143; http://dx.doi.org/10.1038/onc. 2010.319
33. Tannapfel A, John K, Mise N, Schmidt A, Buhlmann S, Ibrahim SM, et al. Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis 2008; 29:211-8; PMID:17984115; http://dx.doi.org/10.1093/carcin/bgm236 (Pubitemid 351201761)
34. Emmrich S, Wang W, John K, Li W, Pützer BM. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Mol Cancer 2009; 8:61; PMID:19671150; http://dx.doi.org/10.1186/ 1476-4598-8-61
35. Sabatino MA, Previdi S, Broggini M. In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs. Int J Cancer 2007; 120:506-13; PMID:17096333; http://dx.doi.org/10.1002/ijc.22362 (Pubitemid 44969020)
36. Müller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005; 12:1564-77; PMID:16195739; http://dx.doi.org/10.1038/sj.cdd.4401774 (Pubitemid 41679162)
37. Conforti F, Sayan AE, Sreekumar R, Sayan BS. Regulation of p73 activity by post-translational modifications. Cell Death Dis 2012; 3:e285; PMID:22419114; http://dx.doi.org/10.1038/cddis.2012.27
38. Becker K, Pancoska P, Concin N, Vanden Heuvel K, Slade N, Fischer M, et al. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Int J Oncol 2006; 29:889-902; PMID:16964385
39. Enoch T, Norbury C. Cellular responses to DNA damage: Cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem Sci 1995; 20:426-30; PMID:8533157; http://dx.doi.org/10.1016/S0968-0004(00)89093-3
40. Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M, et al. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 2002; 21:3796-803; PMID:12032848; http://dx.doi.org/10.1038/sj.onc.1205465 (Pubitemid 34620543)
41. Stiewe T, Pützer BM. p73 in apoptosis. Apoptosis 2001; 6:447-52; PMID:11595834; http://dx.doi.org/10.1023/A:1012433522902 (Pubitemid 33078755)
42. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012; 11:3067-78; PMID:22871739; http://dx.doi.org/10.4161/cc.21476
43. Grob TJ, Novak U, Maisse C, Barcaroli D, Lüthi AU, Pirnia F, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001; 8:1213-23; PMID:11753569; http://dx.doi.org/10.1038/sj. cdd.4400962 (Pubitemid 34048476)
44. Allocati N, Di Ilio C, De Laurenzi V. p63/p73 in the control of cell cycle and cell death. Exp Cell Res 2012; 318:1285-90; PMID:22326462; http://dx.doi.org/10.1016/j.yexcr.2012.01.023
45. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 2000; 289:304-6; PMID:10894779; http://dx.doi.org/10.1126/ science.289.5477.304 (Pubitemid 30469909)
46. Belloni L, Moretti F, Merlo P, Damalas A, Costanzo A, Blandino G, et al. DNp73alpha protects myogenic cells from apoptosis. Oncogene 2006; 25:3606-12; PMID:16652159; http://dx.doi.org/10.1038/sj.onc.1209321 (Pubitemid 43901682)
47. Tissir F, Ravni A, Achouri Y, Riethmacher D, Meyer G, Goffinet AM. DeltaNp73 regulates neuronal survival in vivo. Proc Natl Acad Sci USA 2009; 106:16871-6; PMID:19805388; http://dx.doi.org/10.1073/pnas.0903191106
48. Di CX, Yang LN, Zhang H, An LZ, Zhang X, Ma XF, et al. Effects of carbon-ion beam or X-ray irradiation on anti-apoptosis ?Np73 expression in HeLa cells. Gene 2013; 515:208-13; PMID:23228853; http://dx.doi.org/10.1016/j.gene. 2012.11.040
49. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 2010; 24:549-60; PMID:20194434; http://dx.doi.org/10.1101/gad.1873910
50. Lin Y, Cheng Z, Yang Z, Zheng J, Lin T. DNp73 improves generation efficiency of human induced pluripotent stem cells. BMC Cell Biol 2012; 13:9; PMID:22449255; http://dx.doi.org/10.1186/1471-2121-13-9
51. Taebunpakul P, Sayan BS, Flinterman M, Klanrit P, Gäken J, Odell EW, et al. Apoptin induces apoptosis by changing the equilibrium between the stability of TAp73 and ?Np73 isoforms through ubiquitin ligase PIR2. Apoptosis 2012; 17:762-76; PMID:22484480; http://dx.doi.org/10.1007/s10495-012-0720-7
52. Ory B, Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: P53 family crosstalk meets therapeutic opportunity. Oncotarget 2011; 2:259-64; PMID:21436470
53. Vera J, Schmitz U, Lai X, Engelmann D, Khan FM, Wolkenhauer O, et al. Kinetic Modeling-Based Detection of Genetic Signatures that Provide Chemoresistance via the E2F1-p73/DNp73-miR-205 Network. Cancer Res 2013; PMID:23447575; http://dx.doi.org/10.1158/0008-5472.CAN-12-4095
54. Lee AF, Ho DK, Zanassi P, Walsh GS, Kaplan DR, Miller FD. Evidence that DeltaNp73 promotes neuronal survival by p53-dependent and p53-independent mechanisms. J Neurosci 2004; 24:9174-84; PMID:15483136; http://dx.doi.org/10. 1523/JNEUROSCI.1588-04.2004 (Pubitemid 39372261)
55. Lai D, Visser-Grieve S, Yang X. Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep 2012; 32:361-74; PMID:22762204; http://dx.doi.org/10.1042/BSR20110125
56. Bantel H, Simon HU. DeltaNp73beta is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle 2010; 9:2710-11; PMID:20676032; http://dx.doi.org/10.4161/cc.9.14. 12592
57. Schuster A, Schilling T, De Laurenzi V, Koch AF, Seitz S, Staib F, et al. ?Np73ß is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle 2010; 9:2629-39; PMID:20581467; http://dx.doi.org/10.4161/cc.9.13.12110
58. Leung TH, Ngan HY. Interaction of TAp73 and breast cancer-associated gene 3 enhances the sensitivity of cervical cancer cells in response to irradiation-induced apoptosis. Cancer Res 2010; 70:6486-96; PMID:20647320; http://dx.doi.org/10.1158/0008-5472.CAN-10-0688
59. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117:1370-80; PMID:17446929; http://dx.doi.org/10.1172/JCI30866 (Pubitemid 46718425)
60. Sprung CN, Li J, Hovan D, McKay MJ, Forrester HB. Alternative transcript initiation and splicing as a response to DNA damage. PLoS One 2011; 6:e25758; PMID:22039421; http://dx.doi.org/10.1371/journal. pone.0025758
61. Müller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T. One, two, three-p53, p63, p73 and chemosensitivity. Drug Resist Updat 2006; 9:288-306; PMID:17287142; http://dx.doi.org/10.1016/j.drup.2007.01. 001
62. Liu SS, Chan KY, Leung RC, Law HK, Leung TW, Ngan HY. Enhancement of the radiosensitivity of cervical cancer cells by overexpressing p73alpha. Mol Cancer Ther 2006; 5:1209-15; PMID:16731753; http://dx.doi.org/10.1158/1535-7163.MCT- 05-0451 (Pubitemid 43881313)
63. Pfeifer D, Wallin A, Holmlund B, Sun XF. Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells. J Cancer Res Clin Oncol 2009; 135:1583-92; PMID:19504123; http://dx.doi.org/10. 1007/s00432-009-0606-4
64. Hüttinger-Kirchhof N, Cam H, Griesmann H, Hofmann L, Beitzinger M, Stiewe T. The p53 family inhibitor DeltaNp73 interferes with multiple developmental programs. Cell Death Differ 2006; 13:174-7; PMID:16341031; http://dx.doi.org/10.1038/sj.cdd.4401809
65. Meyer G. p73: A complex gene for building a complex brain. Cell Cycle 2011; 10:1188-9; PMID:21441779; http://dx.doi.org/10.4161/cc.10.8.15297
66. Holembowski L, Schulz R, Talos F, Scheel A, Wolff S, Dobbelstein M, et al. While p73 is essential, p63 is completely dispensable for the development of the central nervous system. Cell Cycle 2011; 10:680-9; PMID:21293190; http://dx.doi.org/10.4161/cc.10.4.14859
67. Pozniak CD, Barnabé-Heider F, Rymar VV, Lee AF, Sadikot AF, Miller FD. p73 is required for survival and maintenance of CNS neurons. J Neurosci 2002; 22:9800-9; PMID:12427836 (Pubitemid 35332864)
68. Zhang J, Chen X. DeltaNp73 modulates nerve growth factor-mediated neuronal differentiation through repression of TrkA. Mol Cell Biol 2007; 27:3868-80; PMID:17353261; http://dx.doi.org/10.1128/MCB.02112-06 (Pubitemid 46726192)
69. Talos F, Abraham A, Vaseva AV, Holembowski L, Tsirka SE, Scheel A, et al. p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis. Cell Death Differ 2010; 17:1816-29; PMID:21076477; http://dx.doi.org/10.1038/cdd.2010.131
70. Billon N, Terrinoni A, Jolicoeur C, McCarthy A, Richardson WD, Melino G, et al. Roles for p53 and p73 during oligodendrocyte development. Development 2004; 131:1211-20; PMID:14960496; http://dx.doi.org/10.1242/dev.01035 (Pubitemid 38443876)
71. Killick R, Niklison-Chirou M, Tomasini R, Bano D, Rufini A, Grespi F, et al. p73: A multifunctional protein in neurobiology. Mol Neurobiol 2011; 43:139-46; PMID:21380933; http://dx.doi.org/10.1007/s12035-011-8172-6
72. Cam H, Griesmann H, Beitzinger M, Hofmann L, Beinoraviciute-Kellner R, Sauer M, et al. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 2006; 10:281-93; PMID:17045206; http://dx.doi.org/10.1016/j.ccr.2006.08.024 (Pubitemid 44512191)
73. Saifudeen Z, Diavolitsis V, Stefkova J, Dipp S, Fan H, El-Dahr SS. Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: Impact on differentiation gene expression. J Biol Chem 2005; 280:23094-102; PMID:15805112; http://dx.doi.org/10.1074/jbc.M414575200 (Pubitemid 40853220)
74. Mattson MP, Ashery U. No more brain tangles with DeltaNp73. Trends Biochem Sci 2009; 34:6-8; PMID:19008105; http://dx.doi.org/10.1016/j.tibs.2008. 10.004
75. Grespi F, Melino G. P73 and age-related diseases: Is there any link with Parkinson Disease? Aging (Albany NY) 2012; 4:923-31; PMID:23271007
76. Hofstetter G, Berger A, Fiegl H, Slade N, Zoric A, Holzer B, et al. Alternative splicing of p53 and p73: The novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene 2010; 29:1997-2004; PMID:20101229; http://dx.doi.org/10.1038/onc.2009.482
77. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Nozoe T, et al. Expression of the p53 family in lung cancer. Anticancer Res 2006; 26(3A):1785-90; PMID:16827107 (Pubitemid 43989432)
78. Daskalos A, Logotheti S, Markopoulou S, Xinarianos G, Gosney JR, Kastania AN, et al. Global DNA hypomethylation-induced ?Np73 transcriptional activation in non-small cell lung cancer. Cancer Lett 2011; 300:79-86; PMID:20926182; http://dx.doi.org/10.1016/j.canlet.2010.09.009
79. Di Vinci A, Sessa F, Casciano I, Banelli B, Franzi F, Brigati C, et al. Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer. Int J Oncol 2009; 34:449-56; PMID:19148480
80. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Pützer BM. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004; 10:626-33; PMID:14760085; http://dx.doi.org/10.1158/1078-0432.CCR- 0153-03 (Pubitemid 38174002)
81. Castillo J, Goñi S, Latasa MU, Perugorría MJ, Calvo A, Muntané J, et al. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. Gastroenterology 2009; 137:1805-15, e1-4; PMID:19664633; http://dx.doi.org/10. 1053/j.gastro.2009.07.065
82. O'Nions J, Brooks LA, Sullivan A, Bell A, Dunne B, Rozycka M, et al. p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer 2001; 85:1551-6; PMID:11720444; http://dx.doi.org/10.1054/bjoc.2001.2138 (Pubitemid 34001589)
83. Guan M, Chen Y. Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: Correlation with Gleason score. J Clin Pathol 2005; 58:1175-9; PMID:16254107; http://dx.doi.org/10.1136/jcp.2005.026955 (Pubitemid 41566462)
84. Cuadros M, Ribas G, Fernández V, Rivas C, Benitez J, Martinez-Delgado B. Allelic expression and quantitative RT-PCR study of TAp73 and DeltaNp73 in non-Hodgkin's lymphomas. Leuk Res 2006; 30:170-7; PMID:16083956; http://dx.doi.org/10.1016/j.leukres. 2005.06.024 (Pubitemid 41773337)
85. Wager M, Guilhot J, Blanc JL, Ferrand S, Milin S, Bataille B, et al. Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients. Br J Cancer 2006; 95:1062-9; PMID:17047653; http://dx.doi.org/10.1038/sj.bjc.6603410 (Pubitemid 44608169)
86. Nekulová M, Zitterbart K, Sterba J, Veselská R. Analysis of the intracellular localization of p73 N-terminal protein isoforms TAp73 and ?Np73 in medulloblastoma cell lines. J Mol Histol 2010; 41:267-75; PMID:20803057; http://dx.doi.org/10.1007/s10735-010-9288-0
87. Zitterbart K, Zavrelova I, Kadlecova J, Spesna R, Kratochvilova A, Pavelka Z, et al. p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival. Acta Neuropathol 2007; 114:641-50; PMID:17912537; http://dx.doi.org/ 10.1007/s00401-007-0298-2 (Pubitemid 350142752)
88. Castellino RC, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM, et al. Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer 2007; 7:127; PMID:17626635; http://dx.doi.org/10.1186/1471-2407-7-127
89. Kumamoto H, Ohki K, Ooya K. Expression of p63 and p73 in ameloblastomas. J Oral Pathol Med 2005; 34:220-6; PMID:15752257; http://dx.doi.org/10.1111/j. 1600-0714.2005.00284.x (Pubitemid 40445155)
90. Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H, et al. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol 2002; 22:2575-85; PMID:11909952; http://dx.doi.org/10.1128/MCB.22.8. 2575-2585.2002 (Pubitemid 34262980)
91. Leupin N, Lüthi A, Novak U, Grob TJ, Hügli B, Graber H, et al. P73 status in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2004; 45:1205-7; PMID:15360002; http://dx.doi.org/10.1080/10298190310001623829 (Pubitemid 38584904)
92. Faridoni-Laurens L, Tourpin S, Alsafadi S, Barrois M, Temam S, Janot F, et al. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: A comparison with p53 mutations. Cell Cycle 2008; 7:1587-96; PMID:18469517; http://dx.doi.org/10.4161/cc.7.11.5894 (Pubitemid 351881326)